Evaluation of a novel blood microsampling device for clinical trial sample collection and protein biomarker analysis-Reference-Cited by-同舟云学术

Evaluation of a novel blood microsampling device for clinical trial sample collection and protein biomarker analysis

Published:2020-07 Issue:13 Volume:12 Page:919-935
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Xing Jinming¹^ORCID,Loureiro Joseph²^ORCID,Patel Michael T¹³,Mikhailov Dmitri¹,Gusev Arkady I¹

Affiliation:

1. Biomarker Development, Novartis Institutes for BioMedical Research, 220 Massachusetts Ave, Cambridge, MA 02139, USA

2. Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, 250 Massachusetts Ave, Cambridge, MA 02139, USA

3. Biopharmaceutical Industry Fellowship Program, Massachusetts College of Pharmacy & Health Sciences University, 179 Longwood Ave, Boston, MA 02115, USA

Abstract

Aim: Evaluation of a novel microsampling device for its use in clinical sample collection and biomarker analysis. Methodology: Matching samples were collected from 16 healthy donors (ten females, six males; age 42 ± 20) via K2EDTA touch activated phlebotomy (TAP) device and phlebotomy. The protein profile differences between sampling groups was evaluated using aptamer-based proteomic assay SomaScan and selected ELISA. Conclusion: Somascan signal concordance between phlebotomy- and TAP-generated samples was studied and comparability of protein abundances between these blood sample collection methods was demonstrated. Statistically significant correlation in selected ELISA assays also confirmed the TAP device applicability to the quantitative analysis of protein biomarkers in clinical trials.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2020-0063

Reference43 articles.

1. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme

2. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies

3. A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies

4. At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials

5. Trends in clinical trial design complexity

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of low volume sampling devices for a pharmacodynamic biomarker analysis: Challenges and solutions;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. Decentralized Clinical Trials in Early Drug Development—A Framework Proposal;Journal of Immunotherapy and Precision Oncology;2024-08-01

3. Enhancing drug development and clinical studies with patient‐centric sampling using microsampling techniques: Opportunities, challenges, and insights into liquid chromatography‐mass spectrometry strategies;Journal of Mass Spectrometry;2024-04-16

4. Self-Powered Microfluidics for Point-of-Care Solutions: From Sampling to Detection of Proteins and Nucleic Acids;Methods in Molecular Biology;2024

5. Digital, Personalized Clinical Trials Among Older Adults: Lessons Learned From the COVID-19 Pandemic and Directions for the Future (Preprint);2023-11-16